Recurrent/Metastatic Olfactory Neuroblastoma: Evaluating the Efficacy and Safety of Nivolumab

This trial evaluates the efficacy and safety of nivolumab monotherapy in patients with recurrent or metastatic olfactory neuroblastoma that is difficult to treat with curative intent. Specifically, nivolumab 240 mg will be administered on Day 1 and Day 15 of each cycle, or nivolumab 480 mg will be administered on Day 1 of each cycle, and this will be continued until disease progression. One cycle is 28 days. The decision on which treatment to administer will be made through consultation between the participant in this trial and their attending physician.

NCT Number	NCT07100704
Lead Sponsor	National Cancer Center Hospital East Collaborators: Japan Research Foundation for Clinical Pharmacology
Conditions	Recurrent/ Metastatic Olfactory Neuroblastoma
Enrollment	14 participants
Start Date	2025-04-15
Primary Completion	2028-04-14 (estimated)
Study Completion	2028-10-14 (estimated)
Updated on ClinicalTrials.gov	2025-08-03